Valuation: CSL Limited

Market Cap 46.5B 40.3B 37.78B 34.45B 64.82B 4,438B 65.86B 445B 174B 2,221B 175B 171B 7,410B P/E 2026 *
-52x
P/E 2027 * 32.4x
Enterprise Value 55.21B 47.86B 44.86B 40.91B 76.97B 5,270B 78.2B 528B 206B 2,638B 207B 203B 8,799B EV / Sales 2026 *
3.59x
EV / Sales 2027 * 3.49x
Free-Float
99.3%
Yield 2026 *
2.94%
Yield 2027 * 3.01%
1 day-0.20%
1 week+3.82%
Current month+11.52%
1 month+11.61%
3 months+41.11%
6 months-9.81%
Current year-20.51%
1 week 131.85
Extreme 131.85
139.03
1 month 113.75
Extreme 113.75
139.03
Current year 90
Extreme 90
184.62
1 year 90
Extreme 90
273.45
3 years 90
Extreme 90
313.55
5 years 90
Extreme 90
319.78
10 years 90
Extreme 90
342.75
Manager TitleAgeSince
Chief Executive Officer 63 2026-02-10
Director of Finance/CFO 52 2025-10-06
Chief Operating Officer - 2025-04-30
Director TitleAgeSince
Director/Board Member 72 2018-10-16
Director/Board Member 70 2011-02-01
Director/Board Member 71 2019-12-08
Date Insider Type Main position Quantity % Market Cap.
2/23/26 Free

Director

263 0.0001%
2/23/26 Free 512 0.0001%
2/19/26 Fiscal year

Director

183 0.0000%
Change 5-day change 1-year change 3-year change Capi.($)
-0.17%+3.82%-49.19%-47.82% 46.91B
+1.00%+4.39%+43.53%-0.12% 79.68B
+0.97%+4.90%-0.37%+26.99% 50.61B
-1.22%-2.62%+15.13%+167.13% 48.81B
+0.85%+2.12%+55.82%-23.03% 30.86B
-0.03%+18.18%+136.71%-37.28% 25.42B
-0.21%+1.81%+40.38%+82.80% 24.48B
-0.42%+4.62%+0.16%+187.03% 21.2B
-3.14%-1.92%+61.19%+161.38% 16.39B
+0.85%+0.63%+62.89%+111.21% 16.18B
Average -0.16%+3.51%+36.63%+62.83% 36.05B
Weighted average by Cap. +0.09%+3.34%+27.99%+44.51%

Financials

2026 *2027 *
Net sales 15.38B 13.33B 12.5B 11.4B 21.44B 1,468B 21.78B 147B 57.45B 735B 57.74B 56.49B 2,451B 15.59B 13.51B 12.67B 11.55B 21.73B 1,488B 22.08B 149B 58.23B 745B 58.53B 57.26B 2,484B
Net income -967M -838M -786M -716M -1.35B -92.26B -1.37B -9.25B -3.61B -46.18B -3.63B -3.55B -154B 1.18B 1.03B 963M 878M 1.65B 113B 1.68B 11.33B 4.42B 56.59B 4.45B 4.35B 189B
Net Debt 8.71B 7.55B 7.08B 6.46B 12.15B 832B 12.34B 83.38B 32.55B 416B 32.72B 32.01B 1,389B 7.98B 6.91B 6.48B 5.91B 11.12B 761B 11.3B 76.32B 29.79B 381B 29.95B 29.3B 1,271B
Logo CSL Limited
CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with approximately 325 plasma collection centers in the United States, Europe and China. The Company operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China (including Hong Kong). Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam, and others.
Employees
29,904
Date Price Change Volume
26-08-13 A$137.62 +0.07% 545,284
26-08-13 A$137.52 -0.66% 1,179,398
26-08-12 A$138.44 +0.08% 1,043,685
26-08-11 A$138.33 +2.87% 1,152,737
26-08-10 A$134.47 +1.72% 837,360
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
97.09USD
Average target price
97.30USD
Spread / Average Target
+0.21%

Quarterly revenue - Rate of surprise